|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 世界胃肠病学组织(WGO-OMGE)临床指南——发展中国家幽门螺杆菌感染显示文摘我非常高兴向大家推荐这份发展中国家幽门螺杆菌(H.priori)临床指南。该指南的编译是由数位在该领域具有丰富临床经验的世界知名专家共同完成的。 | Hunt RH Xiao SD Megraud F Leon-Barua R Bazzoli F Van der Merwe S vaz Coelho LG Fock KM Fedail S Cohen H Malfertheiner P Vakil N Hamid S Goh KL Wong BC Krabshuis JH 杜颖 丛衍群 戴宁 | 2007 | 胃肠病学2007，12，1： | 85 |
| 2 | 国际疼痛研究协会疼痛定义修订版:概念、挑战和折中显示文摘现行国际疼痛研究协会(IASP)将疼痛定义为'与实际或潜在组织损伤,或描述的类似损伤相关的一种不愉快的感觉和情感体验',该定义是由一个分类小组委员会推荐,并于1979年被IASP理事会所采纳。这一定义已被疼痛领域的卫生保健专业人士和研究人员广泛接受,并被一些行业、政府及非政府组织(包括世界卫生组织)所采用。近年来,一些业内人士认为,随着对疼痛更深入的了解,有必要对这个定义重新审定,并提出了修改建议。因此,2018年,IASP成立了一个主席特别工作小组,该小组是由14名来自多个国家的在疼痛相关的临床和基础科学方面拥有广泛专业知识的人员组成,其任务是评估现行定义及其附带注释,并对其保留还是修改提出建议。本文提供了关键概念的摘要、对IASP会员和公众评论的分析以及两年内委员会对疼痛定义和注释的最终修订意见。特别工作小组最后建议将疼痛定义修改为'与组织损伤或潜在组织损伤相关或类似相关的一种不愉快的感觉和情感体验',并将原来的附带注释更新为一系列简要说明并提供相关词源。今年年初,IASP理事会一致接受了修订后的定义和注释。 | Raja SN.Carr DB Cohen M.Finnerup NB Flor H.Gibson S Keefe FJ.Mogil JS Ringkamp M.Sluka KA Song XJ.Stevens B Sullivan MD.Tutelman PR Ushida T.Vader K 程志祥(译) 许继军(译) 程建国(审校) 刘先国(审校) 刘延青(审校) | 2020 | 中华疼痛学杂志2020，16，5： | 137 |
| 3 | Electro-acupuncture to prevent prolonged postoperative ileus:A randomized clinical trial显示文摘AIM:To examine whether acupuncture can prevent prolonged postoperative ileus(PPOI)after intraperitoneal surgery for colon cancer. METHODS:Ninety patients were recruited from the Fudan University Cancer Hospital,Shanghai,China. After surgery,patients were randomized to receive acupuncture(once daily,starting on postoperative day 1, for up to six consecutive days)or usual care.PPOI was defined as an inability to pass flatus or have a bowel movement by 96 h after surgery.The main outcomes were time to first flatus,time to first bowel movement, and electrogastroenterography.Secondary outcomes were quality of life(QOL)measures,including pain, nausea,insomnia,abdominal distension/fullness,and sense of well-being. RESULTS:No significant differences in PPOI on day 4 (P=0.71)or QOL measures were found between the groups.There were also no group differences when the data were analyzed by examining those whose PPOI had resolved by day 5(P=0.69)or day 6(P= 0.88).No adverse events related to acupuncture were reported. CONCLUSION:Acupuncture did not prevent PPOI andwas not useful for treating PPOI once it had developed in this population. | M Kay Garcia Joseph S Chiang Bob Thornton J Lynn Palmer Jennifer McQuade Lorenzo Cohen | 2010 | World Journal of Gastroenterology2010，16，1： | 27 |
| 4 | 世界胃肠病学组织全球指南——发展中国家幽门螺杆菌感染显示文摘世界上有一半人口感染幽门螺杆菌(H.pylori),其感染率因地理位置、种族、年龄和社会经济状况不同而存在很大差异.在发展中国家较高.发达国家较低。但总体而言,近年世界许多地区的H.pylori感染率均呈下降趋势。 | Hunt RH Xiao SD Megraud F Leon-Barua R Bazzoli F van der Merwe S Vaz Coelho LG Fock M Fedail S Cohen H Malfertheiner P Vakil N Hamid S Goh KL Wong BCY Krabshuis J Le Mair A 杜颖 戴宁 | 2011 | 胃肠病学2011，16，7： | 27 |
| 5 | 冠状动脉内皮功能障碍患者循环MOTS-c水平下调显示文摘MOTS-c是一种新发现的线粒体衍生肽,其在调节代谢稳态中起作用。该研究旨在研究在没有显著冠状动脉结构性病变的患者中循环MOTS-c水平是否也与内皮功能障碍相关。方法:纳入无冠状动脉结构性病变的复发性心绞痛并接受冠状动脉造影和内皮功能检测的患者40例。 | Qin Q Delrio S Wan J Jay Widmer R Cohen P Lerman LO Lerman A 刘青 叶鹏 | 2018 | 中华高血压杂志2018，26，2： | 14 |
| 6 | Gastric endoscopic submucosal dissection:From animal model to patient显示文摘AIM:To assess whether the use of porcine models is useful for learning endoscopic submucosal dissection(ESD),thus contributing to its subsequent application in human patients.METHODS:This study/learning process was carried out in 3 phases:PhaseⅠ:Ex vivo animal;PhaseⅡ:In vivo animal;PhaseⅢ:Humans.One endoscopist performed 30 gastric ESDs in porcine models,and later 5gastric ESDs in 5 patients.The ESD was done following the method practiced at the National Cancer Center in Tokyo,Japan.Technical aspects,size,time and speed of ESD,as well as complications were registered.In patients,their clinical,endoscopic and histologic evolution was additionally added.RESULTS:Thirty en bloc ESDs were carried out in animal models.The mean±SD size of the pieces was of28.4±1.2 mm,and the time of ESD was 41.7±2.4min.The time of ESD in the first 15 procedures was 43.0±3.0 min whereas in the next 15 procedures,the time was 40.3±3.9 min,P=0.588.The speed in the first 15ESDs was 1.25±0.11 cm2/min vs 2.12±0.36 cm2/min in the remaining 15,P=0.028.There were no complications.In patients,5 lesions were resected en bloc.The size of the pieces was 25.2±5.1 mm and the time was85.0±25.6 min.Endoscopic and histological controls did not show evidence of residual neoplastic tissue.CONCLUSION:A sequential ESD training program of a unique endoscopist,based on the practice in porcine models,contributed to learning ESD for its subsequent application in humans,yielding good results in efficacy and safety. | Nicolás González Adolfo Parra-Blanco Miguel Villa-Gómez Alejandra Gamba Andrés Taullard Anaulina Silveira Alberto Sanguinetti Carolina Olano Henry Cohen | 2013 | World Journal of Gastroenterology2013，19，45： | 6 |
| 7 | 从附睾到卵子:CRISP蛋白在哺乳动物受精过程中的作用显示文摘哺乳动物的受精过程涉及精卵结合的很多步骤,是一个非常复杂的过程,其分了机制亟待阐明。此篇综述主要论述了CRISP(富含半胱氨酸的分泌蛋白)作为模型分子在哺乳动物受精过程中的价值。大量的体外实验和基因敲出模型研究显示,附睾内的CRISP1以两种不同的亲和力结合于精子表面,参与精子获能、精子-透明带结合、精卵融合的调控。这些研究成果可以延伸至人类。我们住研究中发现,人类具有与啮齿类同源的CRISP(hCRISP1),同样参与受精过样。CRISP家族的其他成员(睾丸内CRISP2、附挈内CRISP3—4、射精时的CRISP3)也参与了精卵结合的过程,提示同源分子间的相互协同有助于受精的成功。另外,我们的研究显示,CRISP蛋白伴随精子穿越男性及女性生殖管道的全过程。我们推测CRISP不仅参与了受精过程,而且可能成为不育和避孕研究的新靶点。 | Vanina G Da Ros Mariana Weigel Munoz Maria A Battistone Nicolas G Brukman Guillermo Carvajal Ludmila Curci Matlas D Gomez-Elias Debora J Cohen Patricia S Cuasnicu | 2015 | Asian Journal of Andrology2015，17，5： | 5 |
| 8 | 网室栽培香蕉耗水特征及合理灌溉水量确定显示文摘主要研究网室和不同灌溉水量下香蕉的耗水特征,确定香蕉的作物系数。处理包括大田充分灌溉处理(100%),网室充分灌溉处理(100%)和亏水处理(5S%),香蕉的耗水量(ET)用热消散茎液流法测定。试验结果显示,在3种处理间香蕉叶面积差异不显著(P〉0.05),网室内香蕉的耗水量比大田降低了44%~55%;网室内2种灌溉水量条件下香蕉蒸散量差异不显著(P〉0.05),说明55%处理灌溉水量已经能够满足香蕉的生长,这个结果也和网室内蒸散量降低值一致。建议当地进行网室内香蕉栽培时,灌溉水量选取大田的一半即可。 | 刘海军 黄冠华 J Tanny S Cohen | 2008 | 灌溉排水学报2008，27，5： | 4 |
| 9 | Is breast conservative surgery a reasonable option in multifocal or multicentric tumors?显示文摘The incidence of multifocal(MF) and multicentric(MC) carcinomas varies widely among clinical studies,depending on definitions and methods for pathological sampling.Magnetic resonance imaging is increasingly used because it can help identify additional and conventionally occult tumors with high sensitivity.However,false positive lesions might incorrectly influence treatment decisions.Therefore,preoperative biopsies must be performed to avoid unnecessary surgery.Most studies have shown higher lymph node involvement rates in MF/MC tumors than in unifocal tumors.However,the rate of local recurrences is usually low after breast conservative treatment(BCT) of MC/MF tumors.It has been suggested that BCT is a reasonable option for MC/MF tumors in women aged 50-69 years,with small tumors and absence of extensive ductal carcinoma in situ.A metaanalysis showed an apparent decreased overall survival in MC/MF tumors but data are controversial.Surgery should achieve both acceptable cosmetic results and negative margins,which requires thorough preoperative radiological workup and localization of lesions.Boost radiotherapy techniques must be evaluated since double boosts might result in increased toxicity,namely fibrosis.In conclusion,BCT is feasible in selected patients with MC/MF but the choice of surgery must be discussed in a multidisciplinary team comprising at least radiologists,surgeons and radiotherapists. | Gilles Houvenaeghel Agnès Tallet Aurélie Jalaguier-Coudray Monique Cohen Marie Bannier Camille Jauffret-Fara Eric Lambaudie | 2016 | World Journal of Clinical Oncology2016，7，2： | 4 |
| 10 | Fondaparinux预防老年急性内科患者发生静脉血栓形成的效果与安全性:随机安慰剂对照研究显示文摘目的:观察 Fondaparinux 对具有中高度静脉血栓发生危险的老年急性内科住院患者的抗凝效果与安全性。设计:双盲随机安慰剂对照研究。背景:8个国家的35个中心。参与者:849例≥60岁内科患者,住院原因分别为充血性心力衰竭、慢性肺病合并急性呼吸系统疾患、急性炎症性或感染性疾病,预期至少住院4天以上。干预:2.5 mg Fondaparinux 或安慰剂,每天1次皮下注射,持续6~14天。观察指标:主要指标为静脉血栓形成(治疗后15天内采用双侧静脉造影检查)及有症状的静脉血栓;次要指标为死亡与出血。患者随访时间为1个月。结果:Fondaparinux 治疗组425例患者和安慰剂组414例患者接受了安全性分析(10例未治疗)。644例患者(75.9%)可接受主要指标分析。静脉血栓检出率在 Fondaparinux 治疗组为5.6%(18/321),安慰剂组为10.5%(34/323),相对危险减少46.7%(95% CI 7.7%~69.3%)。安慰剂组5例患者发生有症状的静脉血栓,Fondaparinux治疗组无患者发生有症状的静脉血栓(P=0.029)。两组均有1例(0.2%)患者发生严重出血。随访结束时,安慰剂组、Fondaparinux 治疗组分别死亡25(6.0%)、14(3.3%)例患者。结论:Fondaparinux 可有效预防急性内科老年患者无症状性及有症状的静脉血栓。严重出血几率两组相似。 | Alexander T Cohen Bruce L Davidson Alexander S Gallus Michael R Lassen Martin H Prins Witold Tomkowski Alexander G G Turpie Jan F M Egberts Anthonie W A Lensing 石汉平(译) 王深明(校) | 2006 | 英国医学杂志中文版2006，9，5： | 3 |
| 11 | Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source显示文摘BACKGROUND The trans-fat containing AMLN(amylin liver non-alcoholic steatohepatitis,NASH)diet has been extensively validated in C57BL/6J mice with or without the Lep^ob/Lep^ob(ob/ob)mutation in the leptin gene for reliably inducing metabolic and liver histopathological changes recapitulating hallmarks of NASH.Due to a recent ban on trans-fats as food additive,there is a marked need for developing a new diet capable of promoting a compatible level of disease in ob/ob and C57BL/6J mice.AIM To develop a biopsy-confirmed mouse model of NASH based on an obesogenic diet with trans-fat substituted by saturated fat.METHODS Male ob/ob mice were fed AMLN diet or a modified AMLN diet with trans-fat(Primex shortening)substituted by equivalent amounts of palm oil[Gubra amylin NASH,(GAN)diet]for 8,12 and 16 wk.C57BL/6J mice were fed the same diets for 28 wk.AMLN and GAN diets had similar caloric content(40%fat kcal),fructose(22%)and cholesterol(2%)level.RESULTS The GAN diet was more obesogenic compared to the AMLN diet and impaired glucose tolerance.Biopsy-confirmed steatosis,lobular inflammation,hepatocyte ballooning,fibrotic liver lesions and hepatic transcriptome changes were similar in ob/ob mice fed the GAN or AMLN diet.C57BL/6J mice developed a mild to moderate fibrotic NASH phenotype when fed the same diets.CONCLUSION Substitution of Primex with palm oil promotes a similar phenotype of biopsyconfirmed NASH in ob/ob and C57BL/6J mice,making GAN diet-induced obese mouse models suitable for characterizing novel NASH treatments. | Michelle L Boland Denise Oro Kirstine S T■lb■l Sebastian T Thrane Jens Christian Nielsen Taylor S Cohen David E Tabor Fiona Fernandes Andrey Tovchigrechko Sanne S Veidal Paul Warrener Bret R Sellman Jacob Jelsing Michael Feigh Niels Vrang James L Trevaskis Henrik H Hansen | 2019 | World Journal of Gastroenterology2019，25，33： | 3 |
| 12 | Review of composite propellant burn rate modeling显示文摘 | Cohen N S | 1980 | AIAA1980，18，3： | 2 |
| 13 | SARS-COV-2 infection(coronavirus disease 2019)for the gastrointestinal consultant显示文摘The current pandemic due to the severe acute respiratory syndrome coronavirus 2 has caused an extreme burden for health care systems globally,and the number of cases is expected to continue to increase,at least in the immediate future.The virus is estimated to have infected more than 1.5 million individuals.The available reports suggest that gastrointestinal(GI)involvement in coronavirus disease 2019(COVID-19)is common and in some cases the GI symptoms may precede the respiratory symptoms.In addition to direct effects of severe acute respiratory syndrome coronavirus 2,the infected patients remain at risk for the complications commonly managed by gastroenterology and hepatology consultants.The most commonly reported GI manifestation of COVID-19 is diarrhea,which is reported in a third to up to more than half of the patients.Mild to moderate elevation of the liver enzymes are also common,although no case of acute liver failure has been reported so far.Many of the medications used for treatment of COVID-19 can also be associated with GI symptoms or liver injury and can be included in the differential diagnosis in these patients.Although the diagnosis of the infection is currently based on RNA analysis in respiratory samples,the available literature on fecal shedding of this virus suggests that fecal RNA testing might prove to be a useful diagnostic test.It is reasonable to delay all non-urgent endoscopic procedures during the peak of the pandemic and use additional protective equipment such as N95 respirators during endoscopy while most patients can be considered high risk for having been exposed to the virus. | Kaveh Hajifathalian Srihari Mahadev Robert E Schwartz Shawn Shah Kartik Sampath Felice Schnoll-Sussman Robert S Brown Jr David Carr-Locke David E Cohen Reem Z Sharaiha | 2020 | World Journal of Gastroenterology2020，26，14： | 2 |
| 14 | Protecting the delivery of heart failure: Regenerative Medicine/Stem Cell Therapeutics:Potential protections afforded by the Department of Health and Human Services and Health Resources Service Administration’s Bureau of Special Programs显示文摘Advances in stem cell science and potential clinical applications have brought clinical medicine closer to the actualization of Regenerative Medicine—an extension of transplantation of organs and cells and implantation of bioprosthetics and biodevices. The goal of such therapeutics will be intervention prior to onset of severe individual disability, enhance organ function and enhance patient performance status without incurring the economic impacts of standard organ transplantation. Regenerative Medicine is already demonstrating proof of principle or efficacy in restora- tion of myocardial contractility, joint mobility and function, immune competence, pulmonary function, immunologic self- tolerance, motor function and normal hemoglobin production with the next targets—diabetes mellitus (type I and type II), neurologic injury, hepatic dysfunction preparing to enter trials. Expenditures on health care needs of an aging U.S. citizenry approximate 20-25% ($3 trillion) of U.S. GDP currently and may to grow to 40% of U.S. GDP by 2025. As the potential of Regenerative Medicine is clinically realized, the societal impact and economic benefits will be disproportionately magnified in the economies of industrialized nations. The experi- ence of the Department of Health and Human Services (HHS), United Network for Organ Sharing (UNOS), the National Bone Marrow Donor Registry (NBMDR), and the National Vaccine Injury Compensation Programs (NVICP) can help ensure that as Regenerative Medicine strives to achieve clinical benefits while avoiding decimation of therapeutic options by product liability and medical malpractice concerns—concerns that crippled the U.S. vaccine manufacturing industry until the creation of the NVICP. The first 50 years of organ/cell/tissue transplantation demonstrates that clinical reality of allogeneic and autologous transplantation can antedate complete understanding of the basic science underlying successful transplantation. Product liability and medical malpractice liability have not impeded the development and growth of organ/cell/tissue transplanta- tion despite increased risks of infection, malignancy and cardiovascular disease in transplant recipients. Currently, human transplantation is only performed using FDA/CBER-approved, non-embryonic stem cells from peripheral blood, bone marrow or umbilical cord blood. Federal legislation passed in 2005 (HR2520 and S1317: The Bone Marrow and Cord Blood Cell Transplantation Program) authorizes the Secretary of Health and Human Services acting through the Director of HRSA to ensure uniform stem cell units distribution and outcomes monitoring via the federally-designated C.W. Bill Young Cell Transplant Program. Historically in the U.S., human biological therapies (vaccines, organ transplant and stem cell transplant) have re- quired federal protections to ensure continued distribution, fair access and avoidance of inhibitory product liability via protections afforded under the “stewardship” of the Secretary of Health and Human Services. The National Childhood Vaccine Injury Act of 1986 established the NVICP to equitably and expeditiously compensate individuals, or families of individuals, who have been declared injured by vaccines, thereby stabilizing a once imperiled vaccine supply by substan-tially reducing the threat of liability for vaccine companies, physicians, and other health care professionals who administer vaccines. Vaccines were the first biologics administered to U.S. citizens en masse and presage stem cell therapeutics (which may similarly be administered to millions) will similarly necessitate that a Stem Cell Injury Compensation Program (SCICP) will also need to be in place to demonstrate an intention to do good, an understanding that industry may do well, but that the health care consumer has a right of protection—all recognized from the outset. The Federal Tort Claims Act (FTCA) addresses liability claims via the Executive, Judicial and Legislative branches of Government, providing an um- brella of liability protection to other participants in the stem cell unit “chain of custody” under the FTCA—similar to the protection from product liability seen in organ and stem cell transplantation for the past 40-50 years. Efficacious development of regenerative medicine capabilities will mandate controlled access must first be provided for individuals with life-threatening diseases without therapeutic options or unable to benefit from or receive proven therapeutic options (ALS, cardiomyopathy and deemed not a candidate for heart transplantation, IDDM with hypoglyce- mic unawareness and no allogeneic source of traditional islet cell replacement available via HRSA) and mandates the prompt adoption of business and legal principles to ensure that the fate of the vaccine manufacturing industry does not become the fate of the stem cell therapeutics industry. If legal and regulatory concerns consume an increasing percentage of health care dollars that could be focused upon innovation, the Regenerative Medicine model will have not realized its full potential. The Diabetes Transplantation/Regenerative Medicine Model is the first organ to cell transplant model outside of oncology to demonstrate the regenerative medicine paradigm. Since all human tissues can be already recapitulated by human stem cells and key patent holders already exist, outlet or distribution of “more-than-minimally-manipulated stem cell units” as an IND approved under FDA/CBER guidelines can be accomplished via the current HHS/HRSA/Dept of Trans- plant methodology. As cardiovascular stem cell researchers develop human therapeutics utilizing more-than-minimally- manipulated stem cell products, they could be afforded protections from product liability historically enjoyed by the transplant community. Extending the Diabetes Transplant/Regenerative Medicine Model to the more than 5 million Americans with chronic heart failure, cell-based therapies to regenerate myocardial contractility could fill an existing void and be delivered in conjunction with and consistent with existing distribution of organs and tissues via HRSA/Department of Transplantation. | Gary S Friedman John S. Tomicki Neil Cohen Robert Marshal Philip Lowry Jeffrey Warsh | 2006 | Journal of Geriatric Cardiology2006，3，3： | 2 |
| 15 | Vascular endothelial growth factor (VEGF) and its receptors显示文摘 | Neufeld G Cohen T Gengrinovitch S | 1999 | FASEB J1999，13，1： | 1 |
| 16 | Multimodal integration--a statistical view 显示文摘 | Wu L Z Oviatt S L Cohen P R | 1999 | IEEE Transactions on Multimedia1999，1，4： | 1 |
| 17 | Histone deacetylase activities are required for innate immune cell control of Thl but not Th2 effector cell function显示文摘 | Brogdon J L Xu Y Szabo S J An S Buxton F Cohen D | 2007 | Blood2007，109，： | 1 |
| 18 | Four different core materials measured for fracture strength in combination with five different designs of endodontic posts显示文摘 | Cohen BI Pagnillo MK Condos S | 1996 | J Prosthet Dent1996，76，5： | 1 |
| 19 | Thermal Frontiers in the Design and Packaging Microelectronic Equipment显示文摘 | Cohen A Bar Kraus A D Davidson S F | 1983 | Mechanical Engineering1983，105，6： | 1 |
| 20 | Serum uric acid and cardiovascular evetlts in successfully treated htpertensive patients 显示文摘 | Alderman MH Cohen H Madhavan S | 1999 | Hypertension1999，34，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员